Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.44 |
| ▸ | GLP1R | P43220 | 3/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.44 |
| ▸ | TFPI | P10646 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | RXFP3 | Q9NSD7 | 4/20 | 0.44 |
| ▸ | RXFP4 | Q8TDU9 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401001 | 0.93 | OPRM1 (0.45) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL4082674 | 0.93 | OPRM1 (0.46) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL4396699 | 0.93 | OPRM1 (0.51) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL4089292 | 0.92 | OPRM1 (0.48) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL4088339 | 0.90 | KISS1R (0.49) | VIPR1VIPR2TFPI | |
| SCHEMBL4082481 | 0.89 | OPRM1 (0.45) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL13723725 | 0.89 | OPRM1 (0.49) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL14404795 | 0.89 | CTSB (0.44) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL13724636 | 0.89 | CTSB (0.45) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL4082915 | 0.88 | REN (0.46) | OPRM1OPRD1OPRK1VIPR1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105119-A1 | ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES | BAYER SCHERING PHARMA AG (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105119-A1 | ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES | ASNS, DNPEP, ANPEP | OPRM1 3788/4885OPRD1 3240/4885OPRK1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.